You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
Boehringer Ingelheim
Baxter
McKesson

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 8,834,873

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,834,873
Title:Method for detecting and controlling cancer
Abstract: Methods are provided for treating cancer metastasis by administering a therapeutic composition targeting a kinase substrate cascade.
Inventor(s): Petricoin, III; Emanuel F. (Gainesville, VA), Pierobon; Mariaelena (Fairfax, VA), Calvert; Valerie (Arlington, VA), Liotta; Lance A. (Bethesda, MD)
Assignee: George Mason Research Foundation, Inc. (Fairfax, VA) Istituto Superiore di Sanita (Rome, IT)
Application Number:12/513,040
Patent Claims:see list of patent claims

Details for Patent 8,834,873

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial George Mason Research Foundation, Inc. (Fairfax, VA) Istituto Superiore di Sanita (Rome, IT) 2026-11-01 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial George Mason Research Foundation, Inc. (Fairfax, VA) Istituto Superiore di Sanita (Rome, IT) 2026-11-01 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial George Mason Research Foundation, Inc. (Fairfax, VA) Istituto Superiore di Sanita (Rome, IT) 2026-11-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Merck
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.